𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Treatment of postinfectious olfactory disorders with minocycline: A double-blind, placebo-controlled study

✍ Scribed by Jens Reden; Birgit Herting; Katja Lill; Robert Kern; Thomas Hummel


Publisher
John Wiley and Sons
Year
2011
Tongue
English
Weight
134 KB
Volume
121
Category
Article
ISSN
0023-852X

No coin nor oath required. For personal study only.

✦ Synopsis


Objectives/Hypothesis: Infection of the upper respiratory tract is one of the most common causes of olfactory loss. One of the possible underlying pathologic pathways is an increase of apoptosis of olfactory receptor neurons. Therefore, treatment with the antibiotic minocycline, which has been shown to act as an antiapoptotic agent, is thought to accelerate improvement of olfactory function. To investigate this idea, 55 patients with postinfectious olfactory dysfunction were tested for their olfactory ability.

Study Design: Randomized, prospective, double-blind, placebo-controlled. Methods: Olfactory function was examined by means of a standardized psychophysical method (Sniffin' Sticks) before and 7 months after a 3-week treatment with either minocycline (2 Â 50 mg/d) or a placebo.

Results: Statistical analyses did not reveal any influence of the treatment on the progress of olfactory function, possibly indicating that pathologic changes other than apoptosis contribute to postinfectious olfactory loss, either on a peripheral level (e.g., scarring/reorganization of the olfactory epithelium) or on a central nervous level.

Conclusions: In conclusion, the present results indicate that minocycline in the given dosage has little or no effect on the recovery of human olfactory function following postinfectious olfactory loss. However, spontaneous recovery is found in approximately 20% of the patients over an observation period of 7 months.


📜 SIMILAR VOLUMES


Treatment of early seropositive rheumato
✍ James R. O'Dell; Gail Paulsen; Claire E. Haire; Kent Blakely; William Palmer; St 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 118 KB 👁 3 views

Objective. Rheumatoid arthritis (RA) causes substantial morbidity and mortality, and current treatments are suboptimal. Recent studies have demonstrated the short-term efficacy of minocycline in the treatment of patients with early RA. This study was undertaken to compare patients treated with conve

Hypericum treatment of mild–moderate dep
✍ E. Schrader; B. Meier; A. Brattström 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 130 KB 👁 2 views

A prospective, randomized, multicentre, double-blind placebo controlled study is described which compares the ecacy and tolerability of hypericum administered as a concentrated ethanolic extract of St John's wort (ZE117) to patients with mild±moderate depression (ICD-10; F 32 . 0 mild; F 32 . 1 mode

Escitalopram in the treatment of general
✍ Jonathan R.T. Davidson; Anjana Bose; Andrew Korotzer; Hongjie Zheng 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 128 KB 👁 2 views

Escitalopram has been shown in clinical trials to improve anxiety symptoms associated with depression, panic disorder, and social anxiety disorder. This study was designed to evaluate the efficacy and tolerability of escitalopram in the treatment of generalized anxiety disorder (GAD). Outpatients (1

A double-blind, placebo-controlled pilot
✍ Farhad Soltani; Mehdi Sayyah; Fariba Feizy; Alireza Malayeri; Amir Siahpoosh; Is 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 82 KB 👁 1 views

## Abstract ## Objective To assess the efficacy and tolerability of ondansetron in combination with selective serotonin reuptake inhibitors (SSRIs) in patients with obsessive‐compulsive disorder (OCD). ## Methods The study was an 8‐week pilot double‐blind randomized clinical trial. Forty‐two adu

Rifaximin for the treatment of active po
✍ Kim L. Isaacs; Robert S. Sandler; Maria Abreu; Michael F. Picco; Stephen B. Hana 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 132 KB 👁 2 views

## Background: The efficacy of the nonabsorbable antibiotic rifaximin in patients with active acute or chronic pouchitis is unknown. ## Methods: We performed a placebo-controlled pilot trial to evaluate the efficacy and safety of rifaximin in patients with active pouchitis. eighteen patients with

Feverfew (Tanacetum parthenium) as a pro
✍ D. Palevitch; G. Earon; R. Carasso 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 65 KB

To assess the effectiveness of feverfew as a prophylactic therapy for migraine, a double-blind placebo controlled cross-over trial was conducted for a period of 4 months. Fifty seven patients who attended an outpatient pain clinic were selected at random and divided into two groups. Both groups were